Case | Age (years) | Gender | CD4 cell count(/μl) | Eyes with FBA | Duration post-ART | ART | Outcome | Treatment |
---|---|---|---|---|---|---|---|---|
Mansour AM et al. 1993 [7] | 27 | M | NM | Left | NM | NM | R | Gancyclovir |
39 | M | NM | Right | NM | NM | R | Gancyclovir | |
24 | M | NM | Left | NM | NM | NM | Gancyclovir | |
35 | M | NM | Left | NM | NM | R | Gancyclovir | |
35 | M | NM | Both | NM | NM | R | Introvenous gancyclovir | |
32 | M | NM | Both | NM | NM | R | Gancyclovir | |
R F Spaide et al. 1992 [8] | 36 | M | 10 | Both | NM | NM | R | Introvenous gancyclovir |
50 | M | 10 | Both | NM | NM | R + retinal detachment | Gancyclovir, vitrectomy,intravenous foscarnet | |
28 | M | 20 | Right | NM | NM | R | Intravenous foscarnet | |
Mehmet Numan Alp et al. 2010 [10] | 36 | F | From 9 to 20 | Both | 6 m | Y NDR | R +retinal detachment | Introvenous gancyclovir, Periocular and topical steroids, ART continuation |
Aguilar Lozano et al. 2016 [11] | 41 | M | 31 | Left | 8 m | Y DR | NM | Introvenous gancyclovir, ART adjustment |
Supinda Leeam-ornsiri et al. 2013 [12] | 40 | F | From 53 to 107 | Right | 1 W | Y NDR | R | Intravitreal ganciclovir injections, Oral prednisone ART continuation |
H F Fine et al. 2001 [13] | 7 | M | 30 | Both | NM | NM | R | Introvenous gancyclovir and foscarnet, Oral prednisone |
Biswas et al. 1999 [14] | 39 | M | 69 | Both | 5 m | Y DR | R +retinal detachment | Introvenous gancyclovir, Vitrectomy, Intravitreal injections of gancyclovir |
S A Geier et al. 1992 [15] | 49 | M | NM | Right | NM | NM | R | Introvenous gancyclovir, Oral fluocortolone |
Feifei Mao et al. 2016 [16] | 26 | M | 11 | Right | 3 W | Y NDR | R | Oral prednisone,intravitreal foscarnet injections, ART continuation |
Our patient | 27 | M | From 33 to 172 | Left | 5 W | Y NDR | R | Intravitreal ganciclovir injection, Introvenous gancyclovir,intravenous foscarnet ART continuation |